Companion animal vaccines are utilized to boost an immune reaction in pets, for example, feline, avian and canine. These immunization products are of different sorts, for example, conjugate vaccines, attenuated live vaccines, subunit vaccines, inactivated vaccines, DNA vaccines, recombinant vaccines and toxoid vaccines. Attenuated live vaccines are imitative from illness-causing pathogens, for example, bacteria or virus that has been deteriorated in laboratory conditions. Conjugate immunizations are a toxoid-containing or antigen readiness which is connected to polysaccharides as well as stimulate the undeveloped immune system to protect against the disease-causing organism. The subunit vaccination is produced using microorganisms, for example, bacteria as well as viruses which have been destroyed by chemical or physical forms. The subunit immunizations, similar to inactivated entire cell immunizations, don’t hold live segments of the pathogen. The toxoid immunizations depend on the contaminant created by specific bacteria that is caused to remain safe and utilized as the antigen in the antibody to inspire an immune reaction. The DNA immunizations are made by embeddings DNA into a bacterial plasmid that works the same as the vector. The recombinant immunizations are delivered by hereditary engineering innovation along with utilizing attenuated infection or bacterium as a vector to acquaint microbial DNA with the cells of the body.
The worldwide market for companion animal vaccines was accounted for approximately US$ 2,100 Million by 2016 and is likely to record a 6.8% CAGR over the conjecture time frame of 2016-2026. The overall market is projected to account for a value of about US$ 4,500 Million through 2026.
Analysis by product type: The overall market is categorized into: Recombinant Vaccines, Conjugate Vaccines, Attenuated Live Vaccines, Subunit Vaccines, Inactivated Vaccines, DNA Vaccines, Toxoid Vaccines; Analysis by species type: The overall market is segmented as: Feline, Avian, Canine
The canine species type segment is projected to record a CAGR of 6.9% during the assessment period, in addition, to be valued at approximately US$ 2,500 Million by the end of 2026. The segment was also projected to gain about 50.9% of market share of the worldwide market for companion animal vaccines by the end of 2016. While the avian species type segment was projected to gain about 14.1% of value share of the worldwide market by the end of the year 2016.
Analysis by distribution channel: The overall market is segmented as: Companion Animal Research Institutes, Companion Animal Hospitals, Companion Animal Clinics; Analysis by region: The overall market is studied across Middle East & Africa, Latin America, North America, Eastern Europe, Western Europe, Japan and Asia Pacific Excluding Japan.
Key market Player: Some of the major players in the worldwide market for companion animal vaccines include Elanco, Boehringer Ingelheim Vetmedica Inc.’s U.S. and Fort Dodge.